Human Reproduction, Vol. 11, No. suppl_3, pp. 33-41, 1996
© 1996 European Society of Human Reproduction and Embryology
GnRH analogues in the treatment of uterine fibroids
Department of Obstetrics and Gynecology, Assaf Harofeh Medical Center (Affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv), Zerifin 70300, Israel
It is now known that gonadotrophin-releasing hormone analogues (GnRHa) are extremely efficient at reducing uterine fibroid volume and reversing the related symptomatology. However, the fibroids tend to return to their pretreatment size about 6 months after discontinuing treatment. GnRHa treatment cannot be continued indefinately due to its potential complications and high cost. It is therefore proposed that GnRHa treatment should be phase one of a two-phase treatment plan for uterine fibroids. The initial course of GnRHa should be followed by either menopause or surgery. Experience with presurgical GnRHa use indicates a defnite treatment advantage and the use of GnRHa as adjuncts to surgery is well established. The value of GnRHa treatment as a alternative to surgery in pre-menopausal patients, however, remains to be established.
Key words: fibroids/GnRH analogues/treatment/uterine tumours